Haleon plc: Update on off-market purchase alongside Pfizer Inc. offering
1 October 2024: Further to its announcement on 30 September 2024, Haleon plc (the "Company" or "Haleon") (LSE/NYSE: HLN) has agreed to make an off-market purchase of 60,526,315 ordinary shares of
The off-market purchase is being made in conjunction with, and subject to the completion of an offering by Pfizer to institutional investors, the results of which have been announced by Pfizer today. The purchase price payable by Haleon to Pfizer for the off-market purchase is
The off-market purchase includes 30,161,278 ordinary shares worth approximately
Separate to the remaining capital allocated to buybacks in 2024, the off-market purchase includes an additional 30,365,037 ordinary shares worth approximately
On completion of the off-market purchase and Pfizer's offering to institutional investors, Pfizer's interest in Haleon's issued ordinary shares with voting rights is expected to reduce from approximately 22.6% to approximately 15.0%.
Brian McNamara, Chief Executive Officer of Haleon commented: "Our purchase of shares from Pfizer will successfully deliver on our commitment to return
The Company will make a further announcement upon completion of the off-market purchase.
Amanda Mellor
Company Secretary
Enquiries
Investors |
Media
|
||
Sonya Ghobrial |
+44 7392 784784 |
Zoë Bird |
+44 7736 746167 |
Rakesh Patel |
+44 7552 484646 |
Gemma Thomas |
+44 7985 175048 |
Emma White |
+44 7823 523562 |
|
|
Email: investor-relations@haleon.com |
Email: corporate.media@haleon.com |
About Haleon
Haleon (LSE/NYSE: HLN) is a global leader in consumer health, with a purpose to deliver better everyday health with humanity. Haleon's product portfolio spans five major categories - Oral Health, Pain Relief, Respiratory Health, Digestive Health and Other, and Vitamins, Minerals and Supplements (VMS). Its long-standing brands - such as Advil, Sensodyne, Panadol, Voltaren, Theraflu, Otrivin, Polident, parodontax and Centrum - are built on trusted science, innovation and deep human understanding.
For more information please visit www.haleon.com
Not for release, publication or distribution in
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.